Free Trial
NASDAQ:NGNE

Neurogene (NGNE) Stock Price, News & Analysis

Neurogene logo
$17.66 +0.57 (+3.34%)
Closing price 04:00 PM Eastern
Extended Trading
$17.62 -0.04 (-0.20%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Neurogene Stock (NASDAQ:NGNE)

Key Stats

Today's Range
$16.86
$18.04
50-Day Range
$7.34
$19.52
52-Week Range
$6.88
$74.49
Volume
128,866 shs
Average Volume
242,277 shs
Market Capitalization
$251.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60
Consensus Rating
Moderate Buy

Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Neurogene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

NGNE MarketRank™: 

Neurogene scored higher than 54% of companies evaluated by MarketBeat, and ranked 497th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neurogene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Neurogene's stock forecast and price target.
  • Earnings Growth

    Earnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurogene is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurogene is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neurogene has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Neurogene's valuation and earnings.
  • Percentage of Shares Shorted

    25.13% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neurogene has recently increased by 3.15%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Neurogene does not currently pay a dividend.

  • Dividend Growth

    Neurogene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.13% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neurogene has recently increased by 3.15%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Neurogene has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Neurogene this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for NGNE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $179,221.00 in company stock.

  • Percentage Held by Insiders

    11.64% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurogene's insider trading history.
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

NGNE Stock News Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
Neurogene (NASDAQ:NGNE) Cut to "Neutral" at Robert W. Baird
Baird Downgrades Neurogene (NGNE)
See More Headlines

NGNE Stock Analysis - Frequently Asked Questions

Neurogene's stock was trading at $22.86 at the start of the year. Since then, NGNE shares have decreased by 23.0% and is now trading at $17.6090.
View the best growth stocks for 2025 here
.

Neurogene Inc. (NASDAQ:NGNE) issued its earnings results on Friday, May, 9th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.03.

Top institutional shareholders of Neurogene include Baker BROS. Advisors LP (10.42%), Redmile Group LLC (9.17%), Blair William & Co. IL (1.06%) and Deutsche Bank AG (1.06%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb.
View institutional ownership trends
.

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/09/2025
Today
5/28/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.60
High Stock Price Target
$72.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+163.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$36.32 million
Pretax Margin
-5,756.43%

Debt

Sales & Book Value

Annual Sales
$925,000.00
Price / Cash Flow
N/A
Book Value
$14.51 per share
Price / Book
1.17

Miscellaneous

Free Float
13,381,000
Market Cap
$241.67 million
Optionable
Optionable
Beta
1.56
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NGNE) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners